"There are a lot of treatment options for patients now, " says Memorial Sloan-Kettering Cancer Center's Robert Motzer, who led the study.
FORBES: Magazine Article
2.
Afinitor delayed disease progression in patients with kidney cancer by a modest three months in a 416-patient trial led by Robert Motzer, an oncologist at Memorial Sloan-Kettering Cancer Center.
FORBES: Health
3.
Memorial Sloan-Kettering's Motzer looks at the big picture.